- Home
- LUXE vs NRIX Comparison
LUXE vs NRIX Comparison
Compare LUXE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUXE
- NRIX
- Stock Information
- Founded
- LUXE 1987
- NRIX 2009
- Country
- LUXE Germany
- NRIX United States
- Employees
- LUXE N/A
- NRIX N/A
- Industry
- LUXE
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- LUXE
- NRIX Health Care
- Exchange
- LUXE NYSE
- NRIX Nasdaq
- Market Cap
- LUXE 1.0B
- NRIX 970.1M
- IPO Year
- LUXE N/A
- NRIX 2020
- Fundamental
- Price
- LUXE $8.21
- NRIX $11.52
- Analyst Decision
- LUXE
- NRIX Strong Buy
- Analyst Count
- LUXE 0
- NRIX 16
- Target Price
- LUXE N/A
- NRIX $29.56
- AVG Volume (30 Days)
- LUXE 141.4K
- NRIX 977.7K
- Earning Date
- LUXE 09-11-2025
- NRIX 07-09-2025
- Dividend Yield
- LUXE N/A
- NRIX N/A
- EPS Growth
- LUXE N/A
- NRIX N/A
- EPS
- LUXE N/A
- NRIX N/A
- Revenue
- LUXE $962,367,055.00
- NRIX $88,381,000.00
- Revenue This Year
- LUXE $48.06
- NRIX $34.87
- Revenue Next Year
- LUXE $114.70
- NRIX N/A
- P/E Ratio
- LUXE N/A
- NRIX N/A
- Revenue Growth
- LUXE 8.74
- NRIX 41.86
- 52 Week Low
- LUXE $3.22
- NRIX $8.18
- 52 Week High
- LUXE $12.50
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- LUXE N/A
- NRIX 46.09
- Support Level
- LUXE N/A
- NRIX $11.13
- Resistance Level
- LUXE N/A
- NRIX $11.92
- Average True Range (ATR)
- LUXE 0.00
- NRIX 0.75
- MACD
- LUXE 0.00
- NRIX -0.13
- Stochastic Oscillator
- LUXE 0.00
- NRIX 11.50
About LUXE LUXEXPERIENCE B.V. SPON ADS EACH RE SPON ADS EACH REP 1 ORD SHS
LuxExperience BV is the digital, multi-brand luxury group and the online shopping destination for luxury enthusiasts. The group operates a portfolio of some of the distinguished store brands in digital luxury and creates communities for luxury enthusiasts with digital and physical experiences. Its brands are MYTHERESA, NET-A-PORTER, MR PORTER, YOOX, and THE OUTNET.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.